Epitel Inc. raised $26 million in a series B financing round that will be used to expand market access for its wireless electroencephalogram (EEG) platform. The Remi remote EEG monitoring system is a wearable device that allows patients to be monitored at home for seizures while continuing their daily activities. It is integrated with the Remi Vigilenz AI system, which uses machine learning to identify and note seizure events.
Suven Life Sciences Ltd. has reported new muscarinic acetylcholine M4 receptor positive allosteric modulators (PAMs) potentially useful for the treatment of schizophrenia, Alzheimer’s disease, Parkinson’s disease, depression, bipolar disorders, Huntington’s disease, attention deficit hyperactivity disorder and pain, among others.
Chengdu Shibeikang Biological Medicine Technology Co. Ltd. has patented new trichloroethanol derivatives potentially useful for the treatment of sleep disorders, anxiety disorders and convulsions.
Biomarin Pharmaceutical Inc. and the n-Lorem Foundation have signed a strategic collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide (ASO) medicine for people with ReNU syndrome, a rare neurodevelopmental condition caused by variants in the RNU4-2 gene.
Dyne Therapeutics Inc. has obtained IND clearance from the FDA for DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD), a rare, genetic disease caused by a mutation in the DUX4 gene. Dyne plans to conduct a phase I trial in ambulatory adults with FSHD.
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated failures of some late-stage programs may reflect not only the complexity of the disease, but also the need to better identify the patients most likely to benefit from each approach.
Maplight Therapeutics Inc. is betting that the next competitive battleground in schizophrenia will be less about whether muscarinic agonists work and more about whether patients can stay on them and whether they offer benefits beyond psychosis.
Otsuka Pharmaceutical Co. Ltd. will likely look next to expand the label of Simtriyo (centanafadine) into patients with comorbid anxiety, having won the U.S. FDA’s green light as a once-daily extended-release capsule for attention deficit hyperactivity disorder (ADHD) in adults plus pediatrics age 6 years and older who weigh at least 20 kg (about 44 lbs.).
With its stock price falling as much as 70% July 27, Capricor Therapeutics Inc. took the rare step of issuing a news release to explain the negative tone of the U.S. FDA’s briefing document for the July 29 Cellular, Tissue and Gene Therapies Advisory Committee meeting to discuss the company’s BLA for deramiocel to treat cardiomyopathy in Duchenne muscular dystrophy.
Alzecure Pharma AB has disclosed UDP-glucuronosyltransferase A1 (UGT1A1; UDPGT 1-1) inhibitors that are potentially useful for the treatment of Lewy body dementia, Creutzfeldt-Jakob disease, frontotemporal dementia, amyotrophic lateral sclerosis, traumatic brain injury, and Parkinson's, Alzheimer's and Huntington's disease, among others.
RSS
